Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Gastric Cancer

Free Subscription Articles published in J Clin Oncol Retrieve available abstracts of 32 articles: HTML format

Single Articles

April 2026
1. WALTER TP, Mazieres J, Otto J, Lena H, et al
   Nivolumab +/- Ipilimumab in Patients With Pretreated Advanced Neuroendocrine Carcinoma: The GCO-001 NIPINEC Randomized Phase II Trial.
   J Clin Oncol. 2026;44:1120-1129.
   PubMed     Abstract available
   
   
   
2. SHAH MA, Kennedy EB, Deighton D, Jhawer M, et al
   Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline Update.
   J Clin Oncol. 2026;44:1145-1165.
   PubMed     Abstract available
   
   
   March 2026
3. ZHENG G, Zhang X, Zhang J, Zheng Z, et al
   Immune Checkpoint Blockade in Deficient Mismatch Repair/Microsatellite Instability-High Gastric Cancer: Solid Evidence or Premature Extrapolation?
   J Clin Oncol. 2026 Mar 12:JCO2502546. doi: 10.1200/JCO-25-02546.
   PubMed    
   
   
   
4. LEONE AG, Raimondi A, Pietrantonio F
   Reply to: Immune Checkpoint Blockade in Deficient Mismatch Repair/Microsatellite Instability-High Gastric Cancer: Solid Evidence or Premature Extrapolation?
   J Clin Oncol. 2026 Mar 12:JCO2503022. doi: 10.1200/JCO-25-03022.
   PubMed    
   
   
   
5. LIU T, Luo S, Yuan X, Liu D, et al
   Trastuzumab Rezetecan in Human Epidermal Growth Factor Receptor 2-Expressing Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma and Colorectal Cancer: A Multicenter, Open-Label, Phase I Trial.
   J Clin Oncol. 2026 Mar 4:JCO2500716. doi: 10.1200/JCO-25-00716.
   PubMed     Abstract available
   
   
   December 2025
6. JIANG Z, Xiang Y, Yi B
   Key Considerations for the Lenvatinib-Pembrolizumab-Chemotherapy Regimen in Advanced Gastric Cancer: Insights From LEAP-015.
   J Clin Oncol. 2025 Dec 11:JCO2502049. doi: 10.1200/JCO-25-02049.
   PubMed    
   
   
   
7. SHITARA K
   Reply to: Key Considerations for the Lenvatinib-Pembrolizumab-Chemotherapy Regimen in Advanced Gastric Cancer: Insights From LEAP-015.
   J Clin Oncol. 2025 Dec 11:JCO2502148. doi: 10.1200/JCO-25-02148.
   PubMed    
   
   
   November 2025
8. RAIMONDI A, Tine G, Ballhausen A, Lonardi S, et al
   Neoadjuvant CTLA-4/PD-(L)1 Blockade Versus Surgery +/- Chemotherapy in Deficient Mismatch Repair/Microsatellite Instability-High Resectable Gastroesophageal Adenocarcinoma: Individual Patient Data Pooled Analysis.
   J Clin Oncol. 2025;43:3457-3467.
   PubMed     Abstract available
   
   
   October 2025
9. SHITARA K, Rha SY, Wyrwicz L, Oshima T, et al
   Pembrolizumab Plus Chemotherapy Versus Chemotherapy as Perioperative Therapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer: Final Analysis of the Randomized, Phase III KEYNOTE-585 Study.
   J Clin Oncol. 2025;43:3152-3159.
   PubMed     Abstract available
   
   
   August 2025
10. ILSON DH
    KEYNOTE-585 Fails While Matterhorn Succeeds in Gastric Cancer: What Lessons Can We Learn?
    J Clin Oncol. 2025 Aug 19:JCO2501439. doi: 10.1200/JCO-25-01439.
    PubMed    
    
    
    
11. SHITARA K, Lorenzen S, Li J, Bai Y, et al
    Lenvatinib Plus Pembrolizumab and Chemotherapy Versus Chemotherapy in Advanced Metastatic Gastroesophageal Adenocarcinoma: The Phase III, Randomized LEAP-015 Study.
    J Clin Oncol. 2025;43:2502-2514.
    PubMed     Abstract available
    
    
    July 2025
12. SEWASTJANOW-SILVA M, Xiao L, Abdelhakeem A, Pabon CM, et al
    Survival Benefit of Palliative Oophorectomy for Patients With Ovarian Metastasis From Baseline Metastatic Gastric Adenocarcinoma.
    J Clin Oncol. 2025;43:2361-2371.
    PubMed     Abstract available
    
    
    
13. KAWAKAMI H, Kadowaki S, Makiyama A, Tsuda M, et al
    Phase II Study (NO LIMIT, WJOG13320G) of First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High Advanced Gastric or Esophagogastric Junction Cancer.
    J Clin Oncol. 2025;43:2184-2195.
    PubMed     Abstract available
    
    
    May 2025
14. SAKAI D, Kadowaki S, Kawabata R, Hara H, et al
    Randomized Phase III Trial of Ramucirumab Beyond Progression Plus Irinotecan in Patients With Ramucirumab-Refractory Advanced Gastric Cancer: RINDBeRG Trial.
    J Clin Oncol. 2025 May 23:JCO2401119. doi: 10.1200/JCO.24.01119.
    PubMed     Abstract available
    
    
    January 2025
15. KLEMPNER SJ, Sonbol MB, Wainberg ZA, Uronis HE, et al
    DKN-01 in Combination With Tislelizumab and Chemotherapy as First-Line Therapy in Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: DisTinGuish.
    J Clin Oncol. 2025;43:339-349.
    PubMed     Abstract available
    
    
    October 2024
16. LI C, Tian Y, Zheng Y, Yuan F, et al
    Pathologic Response of Phase III Study: Perioperative Camrelizumab Plus Rivoceranib and Chemotherapy Versus Chemotherapy for Locally Advanced Gastric Cancer (DRAGON IV/CAP 05).
    J Clin Oncol. 2024 Oct 9:JCO2400795. doi: 10.1200/JCO.24.00795.
    PubMed     Abstract available
    
    
    
17. PAVLAKIS N, Shitara K, Sjoquist K, Martin A, et al
    INTEGRATE IIa Phase III Study: Regorafenib for Refractory Advanced Gastric Cancer.
    J Clin Oncol. 2024 Oct 4:JCO2400055. doi: 10.1200/JCO.24.00055.
    PubMed     Abstract available
    
    
    July 2024
18. KANG YK, Kim HD, Yook JH, Park YK, et al
    Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer: Updated Overall Survival Outcomes From Phase III PRODIGY.
    J Clin Oncol. 2024 Jul 12:JCO2302167. doi: 10.1200/JCO.23.02167.
    PubMed     Abstract available
    
    
    June 2024
19. SORSCHER S
    Helicobacter pylori and Gastric Cancer Screening.
    J Clin Oncol. 2024 Jun 27:JCO2400509. doi: 10.1200/JCO.24.00509.
    PubMed    
    
    
    
20. HEGEWISCH-BECKER S, Mendez G, Chao J, Nemecek R, et al
    First-Line Nivolumab and Relatlimab Plus Chemotherapy for Gastric or Gastroesophageal Junction Adenocarcinoma: The Phase II RELATIVITY-060 Study.
    J Clin Oncol. 2024;42:2080-2093.
    PubMed     Abstract available
    
    
    
21. JANJIGIAN YY, Ajani JA, Moehler M, Shen L, et al
    First-Line Nivolumab Plus Chemotherapy for Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: 3-Year Follow-Up of the Phase III CheckMate 649 Trial.
    J Clin Oncol. 2024;42:2012-2020.
    PubMed     Abstract available
    
    
    
22. BUTT J, Epplein M
    Potent Tool: Helicobacter pylori Treatment to Reduce the Risk of Both Gastric and Colorectal Cancers.
    J Clin Oncol. 2024;42:1865-1867.
    PubMed    
    
    
    March 2024
23. SALANI F, Vivaldi C, Rreka E, Genovesi V, et al
    Surgery and Hyperthermic Intraperitoneal Chemotherapy for Gastric Cancer With Peritoneal Carcinomatosis: The Need for Clear Answers Through Proper Questions.
    J Clin Oncol. 2024 Mar 14:JCO2302611. doi: 10.1200/JCO.23.02611.
    PubMed    
    
    
    February 2024
24. ZHU M, Yoon HH
    Neoadjuvant Immunotherapy in Gastroesophageal Cancer: A Promising Early Signal?
    J Clin Oncol. 2024;42:373-377.
    PubMed    
    
    
    
25. GALLANIS AF, Gamble LA, Samaranayake SG, Lopez R, et al
    Costs of Cancer Prevention: Physical and Psychosocial Sequelae of Risk-Reducing Total Gastrectomy.
    J Clin Oncol. 2024;42:421-430.
    PubMed     Abstract available
    
    
    December 2023
26. MOEHLER M, Xiao H, Blum SI, Elimova E, et al
    Health-Related Quality of Life With Nivolumab Plus Chemotherapy Versus Chemotherapy in Patients With Advanced Gastric/Gastroesophageal Junction Cancer or Esophageal Adenocarcinoma From CheckMate 649.
    J Clin Oncol. 2023;41:5388-5399.
    PubMed     Abstract available
    
    
    November 2023
27. LORENZEN S, Gotze TO, Thuss-Patience P, Biebl M, et al
    Perioperative Atezolizumab Plus Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel for Resectable Esophagogastric Cancer: Interim Results From the Randomized, Multicenter, Phase II/III DANTE/IKF-s633 Trial.
    J Clin Oncol. 2023 Nov 14:JCO2300975. doi: 10.1200/JCO.23.00975.
    PubMed     Abstract available
    
    
    
28. DEL RIVERO J, Perez K, Kennedy EB, Mittra ES, et al
    Systemic Therapy for Tumor Control in Metastatic Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO Guideline.
    J Clin Oncol. 2023;41:5049-5067.
    PubMed     Abstract available
    
    
    October 2023
29. RAU B, Lang H, Koenigsrainer A, Gockel I, et al
    Effect of Hyperthermic Intraperitoneal Chemotherapy on Cytoreductive Surgery in Gastric Cancer With Synchronous Peritoneal Metastases: The Phase III GASTRIPEC-I Trial.
    J Clin Oncol. 2023 Oct 31:JCO2202867. doi: 10.1200/JCO.22.02867.
    PubMed     Abstract available
    
    
    
30. LEE CK, Kim HS, Jung M, Kim H, et al
    Open-Label, Multicenter, Randomized, Biomarker-Integrated Umbrella Trial for Second-Line Treatment of Advanced Gastric Cancer: K-Umbrella Gastric Cancer Study.
    J Clin Oncol. 2023 Oct 26:JCO2300971. doi: 10.1200/JCO.23.00971.
    PubMed     Abstract available
    
    
    September 2023
31. KIM CG, Jung M, Kim HS, Lee CK, et al
    Trastuzumab Combined With Ramucirumab and Paclitaxel in Patients With Previously Treated Human Epidermal Growth Factor Receptor 2-Positive Advanced Gastric or Gastroesophageal Junction Cancer.
    J Clin Oncol. 2023;41:4394-4405.
    PubMed     Abstract available
    
    
    March 2023
32. SHAH MA, Kennedy EB, Alarcon-Rozas AE, Alcindor T, et al
    Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline.
    J Clin Oncol. 2023;41:1470-1491.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Gastric Cancer is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum